Schott Geraldine, Galarza-Muñoz Gaddiel, Trevino Noe, Chen Xiaoting, Weirauch Matthew, Gregory Simon G, Bradrick Shelton S, Garcia-Blanco Mariano A
The University of Texas Medical Branch.
Autoimmunity Biologic Solutions.
RNA. 2021 Feb 10;27(5):571-83. doi: 10.1261/rna.078279.120.
Interleukin 7 receptor α-chain is crucial for the development and maintenance of T cells and is genetically associated with autoimmune disorders including multiple sclerosis (MS), a demyelinating disease of the CNS. Exon 6 of IL7R encodes for the transmembrane domain of the receptor and is regulated by alternative splicing: inclusion or skipping of IL7R exon 6 results in membrane-bound or soluble IL7R isoforms, respectively. We previously identified a SNP (rs6897932) in IL7R exon 6, strongly associated with MS risk and showed that the risk allele (C) increases skipping of the exon, resulting in elevated levels of sIL7R. This has important pathological consequences as elevated levels of sIL7R has been shown to exacerbate the disease in the experimental autoimmune encephalomyelitis mouse model of MS. Understanding the regulation of exon 6 splicing provides important mechanistic insights into the pathogenesis of MS. Here we report two mechanisms by which IL7R exon 6 is controlled. First, a competition between PTBP1 and U2AF2 at the polypyrimidine tract (PPT) of intron 5, and second, an unexpected U2AF2-mediated assembly of spicing factors in the exon. We noted the presence of a branchpoint sequence (BPS) (TACTAAT or TACTAAC) within exon 6, which is stronger with the C allele. We also noted that the BPS is followed by a PPT and conjectured that silencing could be mediated by the binding of U2AF2 to that tract. In support of this model, we show that evolutionary conservation of the exonic PPT correlates well with the degree of alternative splicing of exon 6 in two non-human primate species and that U2AF2 binding to this PPT recruits U2 snRNP components to the exon. These observations provide the first explanation for the stronger silencing of IL7R exon 6 with the disease associated C allele at rs6897932.
白细胞介素7受体α链对T细胞的发育和维持至关重要,并且在基因上与包括多发性硬化症(MS)在内的自身免疫性疾病相关,MS是一种中枢神经系统的脱髓鞘疾病。IL7R的外显子6编码受体的跨膜结构域,并受可变剪接调控:IL7R外显子6的包含或跳过分别导致膜结合或可溶性IL7R异构体。我们之前在IL7R外显子6中鉴定出一个单核苷酸多态性(SNP,rs6897932),它与MS风险密切相关,并表明风险等位基因(C)会增加外显子的跳过,导致sIL7R水平升高。这具有重要的病理后果,因为在MS的实验性自身免疫性脑脊髓炎小鼠模型中,sIL7R水平升高已被证明会加剧疾病。了解外显子6剪接的调控为MS的发病机制提供了重要的机制见解。在这里,我们报告了两种控制IL7R外显子6的机制。第一,PTBP1和U2AF2在内含子5的多嘧啶序列(PPT)处的竞争;第二,外显子中意外的U2AF2介导的剪接因子组装。我们注意到外显子6内存在一个分支点序列(BPS)(TACTAAT或TACTAAC),C等位基因的该序列更强。我们还注意到BPS后面跟着一个PPT,并推测沉默可能由U2AF2与该序列的结合介导。为支持该模型,我们表明外显子PPT的进化保守性与两种非人类灵长类动物中外显子6的可变剪接程度密切相关,并且U2AF2与该PPT的结合将U2 snRNP成分招募到外显子。这些观察结果首次解释了在rs6897932处与疾病相关的C等位基因对IL7R外显子6更强的沉默作用。